# The University of Kansas Cancer Center

> **NIH NIH P30** · UNIVERSITY OF KANSAS MEDICAL CENTER · 2022 · $2,822,506

## Abstract

OVERALL: ABSTRACT
The University of Kansas Cancer Center (KUCC) is a matrix consortium cancer center that includes: The
University of Kansas Medical Center (KUMC), the University of Kansas in Lawrence (KU-L) and via consortium
agreement, the Stowers Institute for Medical Research (Stowers) and Children’s Mercy (CM) Kansas City. In
2020, 171 members of KUCC accounted for $9.7M of NCI funding and a total of $57M in overall cancer-related
funding, an increase of $8M since the last CCSG submission. Supported by an experienced, nationally
recognized leadership team, Roy A. Jensen, MD, has led KUCC on a strong upward trajectory that has been
catalyzed by over $467M philanthropic support since 2004. Over the last four years, substantial progress has
been made broadening partnerships with communities throughout the KUCC catchment area, recruiting highly
innovative physician-scientists, and expanding clinical research and early phase clinical trials. We have also
been advancing education for the next generation of scientists and healthcare providers and heightening the
influence of KUCC researchers in the national scientific community. KUCC has established five aims to ensure
KUCC leads in the fight against cancer:
1. Leverage unique regional assets to transform research discoveries from the laboratory and the clinic to
 drive new anticancer therapeutic development.
2. Provide the optimal environment to focus the power of precision medicine, basic science inquiry, drug
 discovery and development, and behavioral interventions to decrease cancer incidence, morbidity, and
mortality.
3. Lead and implement a comprehensive strategy to educate both the current and next generation of cancer
 researchers and clinicians in cancer research, treatment, prevention, and control.
4. Partner with key stakeholders, community advocates and regional leaders to develop, promote, and foster
 research-based cancer prevention, diagnosis, treatment, control, and survivorship strategies to enhance
 our national impact, improve cancer outcomes and ensure health equity.
5. Advance team science by fostering innovative partnerships and collaborations.
To accomplish these aims KUCC has three research programs: 1) Cancer Biology, 2) Cancer Prevention and
Control, and 3) Drug Discovery, Delivery and Experimental Therapeutics. In addition, KUCC supports the
Clinical Trials Office, seven established shared resources – Biospecimen, Biostatistics and Informatics, Clinical
Pharmacology, Flow Cytometry, Lead Development and Optimization, Nutrition, and Transgenic and Gene-
Targeting – and one developing shared resource – Microscopy & Analytical Imaging.

## Key facts

- **NIH application ID:** 10493583
- **Project number:** 2P30CA168524-11
- **Recipient organization:** UNIVERSITY OF KANSAS MEDICAL CENTER
- **Principal Investigator:** ROY A. JENSEN
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $2,822,506
- **Award type:** 2
- **Project period:** 2012-07-11 → 2027-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10493583

## Citation

> US National Institutes of Health, RePORTER application 10493583, The University of Kansas Cancer Center (2P30CA168524-11). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10493583. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*